REMS For Opioids Still Has A Long Road Ahead; Advisory Committee Is Likely
Executive Summary
A finalized Risk Evaluation and Mitigation Strategy for opioids is a long way off - possibly more than a year - and FDA expects additional stakeholder and industry meetings, as well as a multidisciplinary advisory committee to take place before a program is set in stone
You may also be interested in...
As Opioid REMS Meeting Nears, FDA Notes Worry About Shifting Use To Different Class
In NEJM editorial, FDA's Woodcock suggests "unintended consequences" of any risk management plan for the pain products.
FDA Warns King Of Warning Letter: Firm Got Head Start On Fixing Embeda Ads
FDA's early intervention regarding misleading advertisements for King's morphine product Embeda gave the company a head start on reviewing its promotional pieces, but it did not mean the company could escape from the official warning letter
FDA Warns King Of Warning Letter: Firm Got Head Start On Fixing Embeda Ads
FDA's early intervention regarding misleading advertisements for King's morphine product Embeda gave the company a head start on reviewing its promotional pieces, but it did not mean the company could escape from the official warning letter